Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Botox: Phase III data

In a 52-week U.S. Phase III study in 322

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE